Advertisement

Topics

Companies Related to "Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older" [Most Relevant Company Matches] RSS

00:51 EST 22nd February 2019 | BioPortfolio

Here are the most relevant search results for "Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older" found in our extensive corporate database of over 50,000 company records.

Showing "Safety Immunogenicity Commercially Available Influenza Vaccine Formulation 2006" Companies 1–25 of 2,500+

Extremely Relevant

Vaxin Inc.

Vaxin Inc. is a clinical stage biotechnology company, founded in December 1997 with facilities in Rockville, MD and Birmingham, AL, developing next generation vaccines to address significant public health and biodefense needs. Vaxin is focused on vaccines designed to protect people against influenza and anthrax infection using proprietary, patented technol...


Seqirus

In an industry first, Seqirus has successfully produced cell-based influenza vaccine at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in cells, rather than in eggs.1,2 CVVs are prepared by the World Health Organization (WHO) Global Influenza Surveillance and Response System (GISRS) and associated laboratories, and ...

FluGen, Inc.

FluGen, Inc. is a privately held biotechnology company founded in 2005 and based in Madison, WI. The company has been developing novel influenza vaccine technology first invented at the University of Wisconsin-Madison, in the laboratories of Dr. Yoshihiro Kawaoka and Dr. Gabriele Neumann, and exclusively licensed to FluGen by WARF. The REDEE FLU influenza ...


FluGen

FluGen is an emerging leader in the fight to boost effectiveness of influenza vaccines and other infectious disease products. The company has differentiating technologies that enable it to create value and compete in the large, rapidly growing influenza vaccine market. FluGen is actively advancing a valuable product pipeline that provides the company with ...

Relevant

Sinovac Biotech Ltd.

Sinovac Biotech Ltd. is a China-based biopharmaceutical Company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H...

Sinovac Biotech, Ltd.

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already...

NexBio Incorporated

In recent years the world has witnessed the outbreak of SARS, the worldwide spread of avian influenza viruses, and the escalating outbreaks of avian influenza viruses in humans. The present unavailability of a vaccine against avian influenza infection in humans is of grave concern. Health authorities worldwide fear an imminent and inevitable influenza pandemic in addition to the more routine but ...

Smithers Avanza

Smithers Avanza is a contract research organization known for superior quality, on-time delivery, flexibility, and responsiveness. Our laboratories support the pharmaceutical and chemical industries. At our GLP, cGMP, and AAALAC accredited facilities, our Development Services group offers general toxicology, safety pharmacology, vaccine safety testi...

Geovax Labs

GeoVax is a Biotechnology company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus - AIDS) and other infectious agents. Our goals include: developing AIDS vaccines for global markets, manufacturing and testing these vaccines under GMP/GLP conditions (FDA guidelines), conducting phase I/II and III human trials for vaccine safety and effectiveness and obtaining r...

Inviragen, Inc. and PharmaJet, Inc.

Inviragen is focused on developing vaccines to protect against infectious diseases worldwide. Inviragen's lead product candidate is a vaccine to protect against dengue fever. Inviragen is also developing vaccines to protect against hand, foot and mouth disease and Japanese encephalitis, both of which affect millions of children in Asia. Vaccines in preclin...

AlphaVax, Inc

AlphaVax is developing a new vaccine technology with broad applications against infectious disease, cancer and biodefense threats which has the potential to redefine vaccines and the role they play in medicine. AlphaVax uses a specialized viral vector system to make alphavirus replicon vaccines called alphavaccines, which have shown excellent protection in multiple models for infectious disease an...

Novavax

Novavax Inc. is a biotechnology company committed to leading the global fight against infectious diseases by creating novel, highly potent vaccines that are safer and more effective than current preventive options. Our world-class scientific team is using virus-like particle (VLP) technology to tackle influenza viruses – including avian strains that have the potential to cause a pandemic outbrea...

Sinovac Biotech Ltd.

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). PanfluTM, Sinovac's pandemic influenza vaccine (H5N1), has already b...

Inviragen, Inc. and Duke-NUS

Inviragen is focused on developing vaccines to protect against infectious diseases worldwide. Inviragen's lead product candidate is a vaccine to protect against dengue fever. Inviragen is also developing vaccines to protect against hand, foot and mouth disease, chikungunya and Japanese encephalitis which affect millions of individuals in Asia. Vaccines in ...

Swiss Vaccine Research Institute

The SVRI is a partnership of five research institutes in Switzerland. The SVRI was created in 2007 in Lausanne and is supported by the Swiss Secretariat of Education and Research. Its primary objective is to develop effective preventive vaccine strategies and therapeutic vaccine interventions for infectious diseases and for cancer. SVRI plays an instrument...

Variation Biotechnologies, Inc.

VBI is an emerging leader in the innovative formulation, delivery and development of vaccines. The Company’s powerful, proprietary technology platforms enable thermostable IM and thermostable oral vaccine delivery, creating improved dose equivalent and the potential for dose sparing and adjuvanted vaccines, extending vaccine reach and coverage in established...

Inviragen, Inc.

Inviragen is focused on developing vaccines to protect against infectious diseases worldwide. Inviragen's lead product candidate is a vaccine to protect against dengue fever. Inviragen is also developing vaccines to protect against hand, foot and mouth disease and Japanese encephalitis, both of which affect millions of children in Asia. Vaccines in preclin...

Crucell N.V

Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global biopharmaceutical company focused on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. In 2009 alone, Crucell distributed more than 115 million vaccine doses in more than 100 countries around the world, with the fast majority of doses (97%...

ImmunoBiology Limited (ImmBio)

Limited [ImmBio] is a biotechnology company specialising in the treatment of infectious diseases and cancer. ImmBio's approach is to apply advances in the emerging science of Immunobiology to the development of treatments for infections diseases and cancer. Immbio is developing a proprietary vaccine technology based on these advances. The platform technology is called HspC™ vaccination. HspC...

Variation Biotechnologies Inc

Variation Biotechnologies, Inc. (VBI) creates intelligent vaccines that learn from nature. Our management and scientific team consists of industry-leading experts that have increased our product pipeline and partnerships.After decades of vaccine research, Variosite™ technology evokes the full power of the immune system by mimicking the body's natural protection to infection. This novel vaccine s...

PaxVax, Inc.

PaxVax is a privately held company committed to developing better vaccines to better the world. Established in 2007, PaxVax has a clinical-stage product portfolio, including a cholera vaccine entering Phase 3 and a pandemic H5N1 influenza vaccine entering Phase 2. The company also has vaccines in development for HIV and anthrax under R&D contracts with NIH...

Shoo the Flu

The flu, also called influenza, is a contagious disease that spreads by coughing, sneezing and close contact. Flu symptoms include fever/chills, sore throat, muscle aches, fatigue, cough and headache. The flu is preventable. The flu vaccine is the most effective way to reduce the chances that people will get the flu and spread it to others. The Centers for...

PaxVax Corporation

PaxVax is a privately held company established in 2007 to develop and commercialize innovative and socially responsible vaccines against infectious diseases. PaxVax has a clinical-stage product portfolio, including a cholera vaccine entering Phase 3 and a pandemic H5N1 influenza vaccine entering Phase 2. The company also has vaccines in development for HIV...

VBI Vaccines

VBI Vaccines is a biotechnology company dedicated to the innovative formulation, development and delivery of safe and effective vaccines that expand and enhance vaccine protection in both established and emerging markets. VBI’s innovative approach to vaccine development and growing pipeline of vaccine programs address significant market opportunity an...

Redbiotec

Redbiotec is a privately held Swiss biopharmaceutical company founded in 2006 and based in Zurich-Schlieren. The company uses its proprietary rePAX® co-expression technology for the efficient generation of multi-component virus-like particles (VLPs) and other protein assemblies. The company entered the field of VLP vaccines in 2008 and currently has ...


More From BioPortfolio on "Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks